Click here to read the newsletter.
Since our listing on First North in March 2016, Xintela has had an intense period and we have been working at a high tempo with our ongoing projects. In order to keep our investors and other stakeholders informed about the company and our development, we plan to publish newsletters periodically.
In our newsletters, we will present updates and more detailed information on our own work and on advances in the fields in which we are active. We will also summarise important events. It is our hope that you will find our newsletters interesting and that they will help to keep you updated on Xintela. We have already made great progress in 2016 and we intend to continue to advance at the same rate.
In this newsletter, we will update our readers regarding our study of the treatment of cartilage damage in horses. In addition, we will summarise our impressions from Xintela's recent participation in a conference in Japan.
It is also gratifying that Xintela has attracted attention in the media recently e.g. in the journal Entreprenör and on a New Zealand news page regarding horses and horse health. In this newsletter, you can also read a commentary about a publication in the international journal Molecular Therapy — Methods & Clinical Development, in which I am a co-author.
I hope that this and coming newsletters are both informative and useful for Xintela's shareholders and other followers.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO